Similar to the data in MDS, the majority of mutations occurred in hotspot areas: K666N and K700E in SF3B1, S34 and Q157 in U2AF1 and P95 in SRSF2. The incidence of SF mutations in AML varied from 4.5%-12.5% in different reports.[2, 8-11] Yoshida et al found SF3B1, U2AF1 and SRSF2 mutations in 2.6%, 1.3% and 0.7%, respectively, of 151 AML patients.[2] Kihara et al reported 4.5% of 197 patients harbored SF mutations, including SF3B1 (1.5%), U2AF1 (1.5%), SRSF2 (1%) and ZRSR2 (0.5%) mutations. The gene discussed is ZRSR2; the disease is myelodysplastic syndrome.